Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
J Heart Valve Dis ; 13(2): 239-46; discussion 246-7, 2004 Mar.
Article in English | MEDLINE | ID: mdl-15086263

ABSTRACT

BACKGROUND AND AIM OF THE STUDY: The Mosaic valve is a third-generation stented porcine bioprosthesis built upon the historical durability of the Hancock II valve in an attempt to improve hemodynamic performance and durability. METHODS: This multicenter trial was prospective and non-randomized in design. Between February 1994 and October 1999, six centers following a common study protocol enrolled 797 patients (mean age 70 years: range: 21-88 years) who underwent aortic valve replacement (AVR), and 232 patients (mean age 68 years; range: 17-84 years) who underwent mitral valve replacement (MVR). The cumulative follow up was 3,442 patient-years (pt-yr) for AVR (mean 4.3 years; maximum 8 years), and 870 pt-yr for MVR (mean 3.7 years; maximum 7 years). Follow up was complete for 95% of AVR patients, and for 97% of MVR patients. RESULTS: The mean gradient and calculated effective orifice area average across all valve sizes remained stable at one, four and six years. Freedom from valve-related adverse events (mean +/- SE) at one, four and seven years after AVR were, respectively: Antithromboembolic-related hemorrhage (ARH) 97.0 +/- 0.6, 95.6 +/- 0.9, and 94.6 +/- 5.1%; primary hemolysis 100, 100, and 100%; and structural valve deterioration (SVD) 100, 100 and 100%. Freedom at one, four and seven years after MVR were: ARH 96.9 +/- 1.2, 95.6 +/- 2.0, and 95.6 +/- 7.6%; primary hemolysis 100, 100, and 100%; and SVD 100, 100, and 100%. CONCLUSION: These mid-term results demonstrate the clinical safety and excellent performance of the Mosaic valve. Continued follow up will determine if this new-design, third-generation bioprosthesis will provide increased durability.


Subject(s)
Bioprosthesis , Heart Valve Prosthesis , Adult , Aged , Aged, 80 and over , Aortic Valve/surgery , Bioprosthesis/adverse effects , Equipment Safety , Female , Fibrinolytic Agents/therapeutic use , Follow-Up Studies , Heart Valve Diseases/mortality , Heart Valve Diseases/surgery , Heart Valve Prosthesis/adverse effects , Humans , Male , Middle Aged , Mitral Valve/surgery , Platelet Aggregation Inhibitors/therapeutic use , Postoperative Complications/drug therapy , Postoperative Complications/etiology , Postoperative Complications/mortality , Prospective Studies , Prosthesis Design , Severity of Illness Index , Survival Analysis , Time , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...